PYXS Earnings & Financial Statements
Pyxis Oncology, Inc.
$1.82
+$0.02(+1.40%)
37
Overall
60
Value
18
Tech
34
Quality
Market Cap
$214.05M
Volume
155.51K
52W Range
$1.03 - $4.15
Target Price
$8.44
PYXS earnings and financial statements: Pyxis Oncology, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
PYXS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $13.86M | $16.15M | $1.78M | - | - |
| Cost of revenue | $2.39M | $475.0K | - | - | - |
| Operating income | -$84.42M | -$89.46M | -$82.20M | -$123.48M | -$69.72M |
| EBITDA | -$73.72M | -$76.51M | -$71.86M | -$120.01M | -$75.38M |
| Net income | -$79.62M | -$77.33M | -$73.79M | -$120.72M | -$75.97M |
| EPS (diluted) | $-1.28 | $-1.32 | $-1.85 | $-3.65 | $-8.95 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $91.52M | $157.18M | $173.73M | $211.38M | $280.02M |
| Total liabilities | $38.11M | $36.43M | $48.02M | $50.55M | $18.71M |
| Shareholders’ equity | $53.41M | $120.75M | $125.70M | $160.82M | $261.31M |
| Cash and equivalents | $15.42M | $19.47M | $9.66M | $179.29M | $274.74M |
| Long-term debt | $16.98M | $18.75M | $20.10M | $18.92M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$63.50M | -$57.67M | -$70.71M | -$89.33M | -$35.33M |
| Capital expenditure | -$9.0K | -$237.0K | -$6.73M | -$6.40M | -$540.0K |
| Free cash flow | -$63.51M | -$57.91M | -$77.44M | -$95.73M | -$35.87M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PYXS | $1.82 | +1.4% | 155.51K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |